Coherus BioSciences Inc. (NASDAQ:CHRS) and Aptevo Therapeutics Inc. (NASDAQ:APVO), both competing one another are Biotechnology companies. We will compare their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Coherus BioSciences Inc.||37.10M||32.65||185.05M||-3.13||0.00|
|Aptevo Therapeutics Inc.||23.07M||1.52||53.69M||-2.21||0.00|
Table 1 highlights Coherus BioSciences Inc. and Aptevo Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.
Table 2 demonstrates the net margins, return on assets and return on equity of Coherus BioSciences Inc. and Aptevo Therapeutics Inc.
|Net Margins||Return on Equity||Return on Assets|
|Coherus BioSciences Inc.||-498.79%||-742.4%||-126.3%|
|Aptevo Therapeutics Inc.||-232.73%||-78.8%||-51.1%|
Coherus BioSciences Inc.’s Current Ratio and Quick Ratio are 5.3 and 5.3 respectively. The Current Ratio and Quick Ratio of its competitor Aptevo Therapeutics Inc. are 3.9 and 3.7 respectively. Coherus BioSciences Inc. therefore has a better chance of paying off short and long-term obligations compared to Aptevo Therapeutics Inc.
The following table shown below contains the ratings and recommendations for Coherus BioSciences Inc. and Aptevo Therapeutics Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Coherus BioSciences Inc.||0||0||2||3.00|
|Aptevo Therapeutics Inc.||0||0||0||0.00|
Coherus BioSciences Inc.’s upside potential currently stands at 43.10% and an $25 consensus target price.
Institutional & Insider Ownership
Institutional investors held 98.8% of Coherus BioSciences Inc. shares and 32.2% of Aptevo Therapeutics Inc. shares. Insiders held roughly 0.4% of Coherus BioSciences Inc.’s shares. Competitively, Aptevo Therapeutics Inc. has 1% of it’s share held by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Coherus BioSciences Inc.||1.49%||11.66%||36.64%||-25.41%||53.37%||66.08%|
|Aptevo Therapeutics Inc.||-12.8%||-10.63%||-37%||-72.97%||-52.96%||12.6%|
For the past year Coherus BioSciences Inc. was more bullish than Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. beats on 6 of the 11 factors Coherus BioSciences Inc.
Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The companyÂ’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, nonÂ–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, BehÃ§et’s Disease, CrohnÂ’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Aptevo Therapeutics Inc., a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn. The companyÂ’s marketed products also comprise HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B; and VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals. Its investigational stage product candidates include MOR209/ES414, a bispecific immunotherapeutic protein that is in Phase I clinical trial for metastatic castration-resistant prostate cancer; ES210, a bispecific protein therapeutic that is in pre-clinical development stage for inflammatory bowel diseases; otlertuzumab, a monospecific protein therapeutic that is in Phase II clinical trial for chronic lymphocytic leukemia; ROR1, a bispecific immunotherapeutic protein that is in preclinical development; APVO436, a bispecific protein therapeutic, which is in pre-clinical development; and other therapeutic protein product candidates for cancer. The company was incorporated in 2016 and is based in Seattle, Washington.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.